Clinical Trials · NCT06573398
Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC
- Phase
- Phase 2
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Ruijin Hospital
- Enrollment
- 20
- Start date
- Sep 2024
- Locations
- See registry
- Primary endpoint
- R0 resection rate